Oncolytic virus therapy refers to the biological therapy of tumors, using live viruses with relative tumor selectivity. Replication-restricted virus strains have been genetically engineered, which replicate selectively within tumor cells. Examples include replication-competent mutants of herpes virus, adenovirus, vesicular stomatitis virus, reovirus, and measles virus (2, 17, 37, Martuza, 2000; 56, 63). In particular, replication-competent recombinant HSV strains may offer distinct advantages in oncolytic therapy of epithelial tumors: (a) HSV is highly infectious to tumors of epithelial origin, resulting in high efficacy (70); (b) there is considerable redundancy in HSV receptors, which makes the loss of HSV receptors by tumors due to mutations less likely; (c) antiherpetic drugs are commercially available, which may be used clinically to control undesired side effects, should local or systemic spread of the virus occur; and (d) because of its large genome, HSV offers ample packaging opportunities – up to 30 kb – without affecting viral replication in cancer cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this paper
Cite this paper
Benencia, F., Coukos, G. (2008). Biological Therapy with Oncolytic Herpesvirus. In: Coukos, G., Berchuck, A., Ozols, R. (eds) Ovarian Cancer. Advances in Experimental Medicine and Biology, vol 622. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68969-2_18
Download citation
DOI: https://doi.org/10.1007/978-0-387-68969-2_18
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-68966-1
Online ISBN: 978-0-387-68969-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)